Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[21] Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Nakamura, Y.
Namikawa, K.
Yoshino, K.
Yoshikawa, S.
Uchi, H.
Goto, K.
Fukushima, S.
Kiniwa, Y.
Takenouchi, T.
Uhara, H.
Kawai, T.
Hatta, N.
Funakoshi, T.
Teramoto, Y.
Otsuka, A.
Doi, H.
Ogata, D.
Matsushita, S.
Isei, T.
Hayashi, T.
Shibayama, Y.
Yamazaki, N.
ANNALS OF ONCOLOGY, 2020, 31 (09) : 1198 - 1206
[22] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Gide, Tuba N.
Quek, Camelia
Menzies, Alexander M.
Tasker, Annie T.
Shang, Ping
Holst, Jeff
Madore, Jason
Lim, Su Yin
Velickovic, Rebecca
Wongchenko, Matthew
Yan, Yibing
Lo, Serigne
Carlino, Matteo S.
Guminski, Alexander
Saw, Robyn P. M.
Pang, Angel
McGuire, Helen M.
Palendira, Umaimainthan
Thompson, John F.
Rizos, Helen
da Silva, Ines Pires
Batten, Marcel
Scolyer, Richard A.
Long, Georgina V.
Wilmott, James S.
CANCER CELL, 2019, 35 (02) : 238 - +
[23] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Gauci, Marie-Lea
Boudou, Philippe
Baroudjian, Barouyr
Vidal-Trecan, Tiphaine
Da Meda, Laetitia
Madelaine-Chambrin, Isabelle
Basset-Seguin, Nicole
Bagot, Martine
Pages, Cecile
Mourah, Samia
Resche-Rigon, Matthieu
Pinel, Sylvine
Sassier, Marion
Rouby, Franck
Eftekhari, Pirayeh
Lebbe, Celeste
Gautier, Jean-Francois
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
[24] Anti-PD-1 therapies- a new first-line option in advanced melanoma
Sullivan, Ryan J.
Flaherty, Keith T.
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (11) : 625 - 626
[25] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Subrahmanyam, Priyanka B.
Dong, Zhiwan
Gusenleitner, Daniel
Giobbie-Hurder, Anita
Severgnini, Mariano
Zhou, Jun
Manos, Michael
Eastman, Lauren M.
Maecker, Holden T.
Hodi, F. Stephen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[26] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
Kudo, Masatoshi
LIVER CANCER, 2019, 8 (06) : 413 - 426
[27] Prognostic factors for survival in patients with metastatic skin melanoma, receiving first- line treatment with anti-PD-1 or anti-PD-1 and anti-CTLA-4 immunotherapy regimen at the Instituto Nacional de Cancerolog?a (Bogot?, Colombia)
Marcela Zuluaga-Liberato, Andrea
Eduardo Bonilla-Gonzalez, Carlos
Contreras-Mejia, Fernando
Alexander Carreno-Duenas, Jose
REVISTA COLOMBIANA DE CANCEROLOGIA, 2023, 27 (01): : 91 - 102
[28] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Parakh, Sagun
Park, John J.
Mendis, Shehara
Rai, Rajat
Xu, Wen
Lo, Serigne
Drummond, Martin
Rowe, Catherine
Wong, Annie
McArthur, Grant
Haydon, Andrew
Andrews, Miles C.
Cebon, Jonathan
Guminski, Alex
Kefford, Richard F.
Long, Georgina V.
Menzies, Alexander M.
Klein, Oliver
Carlino, Matteo S.
BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1558 - 1563
[29] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Ellebaek, Eva
Khan, Shawez
Bastholt, Lars
Schmidt, Henrik
Haslund, Charlotte Aaquist
Donia, Marco
Svane, Inge Marie
EUROPEAN JOURNAL OF CANCER, 2024, 198
[30] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Su, Xin
Li, Jian
Xu, Xiao
Ye, Youbao
Wang, Cailiu
Pang, Guanglong
Liu, Wenxiu
Liu, Ang
Zhao, Changchun
Hao, Xiangyong
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)

← 1 2 3 4 5 →